Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of BPI-7711 capsules in treatment-naive EGFR-mutant advanced or recurrent metastatic non-small cell lung cancer
CTR20190442Phase 3Active
- Sponsor
- Betta Pharmaceuticals
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rezivertinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Apr 2021; status: active.
02
Drugs
rezivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190442.